Kineticos Life Sciences’ Post

Business Models in Pharma and HealthCare sector ➡ The pharmaceutical sector is undergoing a massive transformation, as well as expansion and diversification of products beyond the pill ➡ The digital revolution and technology are undoubtedly the disruptive and driving forces behind this transformation, but they are not the only ones. The holistic approach to medicine and a broader concept of health, which takes into account wellness, or the entry of new players and the creation of new work and business models are also relevant ➡ In this context, Innovation becomes an essential pillar to respond to these challenges and, above all, to transform opportunities into realities A tailor-made training to go deeper into the so-called "P-medicine": Personalized, Preventive, Predictive, Precision, Participatory, Patient-centered, Population-based ---- CAIXA RESEARCH INSTITUTE CaixaResearch Institute, a new health and life sciences research and innovation centre, the first one specialised in immunology in Spain –The CaixaResearch Institute will be dedicated to studying how the immune system works when it interacts with the most prevalent pathologies, such as neurological, oncological and infectious diseases, as well as analysing related environmental factors –Four research centres are part of the initiative as CaixaResearch Associated Centres: the IrsiCaixa AIDS Research Institute, the Barcelona Institute for Global Health (ISGlobal), Vall d'Hebron Institute of Oncology (VHIO)) and the Barcelonaβeta Brain Research Center (BBRC), the research institute of Fundación Pasqual Maragall A pleasure to extend and strengthen my collaboration with the ecosystem Fundación ”la Caixa” Great session with key roles in these organizations: Marina Espriu, Lucie Rabattu, Oscar Casado Vilches, Teresa Puigferrat Pérez, Nestor Huerta Baño, Mario De la Cuesta Rivero, Cristina Val Cid, José Luis Pérez Guillamón, Carolina Minguillon, Paula Mera Nanín, PhD, Mònica Montserrat, Carlos Pérez Flores, Lídia Aguilera, Alba Velasco Trujillo, E. Ramona Popescu, Laurent Ladépêche #innovation #healthcare #pharma #research #science #businessmodels #patients #medicine

Association for Diagnostics & Laboratory Medicine Disruptive Technology Award semi-finalists were announced! After grouping the innovations, there is a 33.3% chance each for infectious disease and blood sampling, and 16.6% for oncology and mental health, I am curious to see if the judges deviate from historical trends favoring infectious disease (only 1 out of 6 past winners). Babson Diagnostics | BetterWay Blood Testing Offers a less invasive, convenient service at retail locations. Provides lab-quality results from microsamples (fingerstick). Set for summer 2024 launch, with key patents. Dionysus Digital Health | The Enlighten Test Uses AI to analyze genetic/epigenetic, and behavioral data to manage mood disorders. Uses a smartphone app for real-time mood tracking, targeting women’s health issues like postpartum depression. MELIOLABS INC. | MeltStat Three hour culture-free pathogen detection directly from blood, reducing antibiotic misuse. Integrates AI with microfluidics for accurate diagnostics, focusing on neonates. Mercy BioAnalytics, Inc. | Mercy Halo™ Uses extracellular vesicles for sensitive ovarian cancer detection. Offers a potential low-cost annual screening solution to enhance survivability. PBD Biotech | Actiphage TB Test Combines phage technology with qPCR for specific TB detection. Supports the World Health Organization End TB Strategy, aiming for scalable global use. Vitestro | Autonomous blood drawing device Features robotic phlebotomy to address workforce shortages, enhancing safety and standardizing procedures. Launching in Europe in 2024, well-received in tests. Learn more about the semi-finalists here: https://lnkd.in/eHEHquMK #adlm #aacc #labtesting #diagnostics

𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗥𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝘀 𝗮 𝗖𝗼𝗺𝗽𝗲𝗹𝗹𝗶𝗻𝗴 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗱𝘂𝗲 𝘁𝗼 𝗶𝘁𝘀 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝘁𝗼 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗯𝘆 𝗧𝗮𝗶𝗹𝗼𝗿𝗶𝗻𝗴 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝘁𝗼 𝗜𝗻𝗱𝗶𝘃𝗶𝗱𝘂𝗮𝗹 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 💊 Precision medicine, sometimes known as personalized medicine, is a way healthcare providers can offer and plan specific patient care based on the particular genes, proteins, and other substances in a person’s body. This is largely based on knowing the effects of changes in specific genes (and proteins) inside cells. In precision medicine, doctors use information from lab tests to put together a plan of care that usually includes specific recommendations. 💊The global oncology precision medicine can grow at a CAGR of 11.2 % until 2030. The Asia Pacific region may have the largest CAGR. The non-oncology precision medicine size may increase up to 130 billion dollars by 2030 Read More: https://lnkd.in/dbRG-XXj Connect with 𝐒𝐭𝐞𝐥𝐥𝐚𝐫𝐢𝐱 for cutting-edge industry insights, perspectives, and Business purposes [https://lnkd.in/dpJutC_F] Stay tuned to 𝐒𝐭𝐞𝐥𝐥𝐚𝐫𝐢𝐱 for more thought-provoking and insightful posts. [https://stellarix.com/] Follow #Stellarix for the latest exciting developments and updates [https://lnkd.in/ddyE7tqK] #PrecisionMedicine #PersonalizedMedicine #HealthcareInnovation

Are we better than #AI at finding new solutions for pharmacy within drug #repositioning? 🤔 The future is still in the hands of experts! Excited to share our latest publication, "One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing," which would not have been possible without the co-authors Professor Piotr Fiedor, a distinguished surgeon and transplantologist, and Professor Bo Michniak - Kohn, an expert in topical skin delivery. 👨⚕️🔬 Their immense knowledge and experience were indispensable in bringing this research to life! 📖 Read more: https://lnkd.in/gAP7A_it In this study, we explore the innovative use of cardiovascular drugs to enhance wound healing, showcasing their potential beyond traditional applications. Our findings suggest these agents could revolutionize treatments and offer new hope for patients with chronic wounds! 💊 We are grateful for the collaboration with these outstanding researchers and look forward to future endeavors together. 🙌👏 #PharmacyInnovation #WoundHealing Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

🚀 Significant Progress in Precision Medicine for Long COVID & ME/CFS 🧬 PrecisionLife, under the leadership of CEO Dr. Steve Gardner, has recently achieved a major milestone in its ongoing efforts to combat long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The company has returned groundbreaking results from a 1,000-patient clinical trial conducted in partnership with the Metrodora Institute in Salt Lake City. This trial is crucial in validating PrecisionLife's innovative genotypic diagnostic test, which is set to revolutionize the approach to precision medicine. 🔍 Key Developments: PrecisionLife’s advanced combinatorial analytics have led to the identification of 73 novel genes linked to severe long COVID, many of which overlap with ME/CFS and other complex diseases. This discovery provides a deeper understanding of the genetic mechanisms behind these conditions. The company is paving the way for personalized treatment options, including drug repurposing strategies that target specific patient subgroups with mitochondrial, autoimmune, or neurotransmitter dysfunctions. 🌍 Impact and Innovation: These advancements hold the potential to significantly transform the diagnostic and treatment landscape for millions of patients who have long been underserved. By focusing on the underlying causes rather than just the symptoms, PrecisionLife is setting new standards in healthcare. 🔬 Oxford: The Innovation Hub Operating from its headquarters in Oxford, UK, Precision Life is leveraging the area’s strong academic and biotech ecosystem to drive innovation in computational biology and precision medicine. This strategic location supports the company’s global initiatives, including its partnership with the Metrodora Institute. Together, PrecisionLife and Metrodora Institute are rapidly advancing the development of life-changing diagnostics and treatments for patients in need. Stay tuned for more updates as these efforts continue to progress. #PrecisionMedicine #LongCOVID #MECFS #Genomics #HealthcareInnovation #Oxford

Prof. Riccardo Polosa meets the international partners of the THRUST project in Munich to share and analyze the data collected so far and to strategically plan the next months. The #thrust project is the latest initiative carried out by #CoEHAR in Catania. The project, conceived and coordinated by prof. Riccardo Polosa, aims to evaluate smoking-related respiratory endpoints through innovative tools and the analysis of new biomarkers. Considering that #cigarette smoking leads to progressive structural damage and functional alterations in the lungs, the project aims to use innovative computerized imaging systems combined with artificial intelligence to detect early changes caused by smoking in the respiratory tract. #stopsmoking #research Stefano Palmucci https://lnkd.in/eYXrDdf4

❗Take a look at the innovative work by INCLIVA Instituto de Investigación Sanitaria in Spain! 🎗 This study focuses on understanding the effects of adjuvant #endocrine therapy with aromatase inhibitors on the bone health of #breastcancer #patients to improve their #treatments. This significantly contributes towards personalised treatment for #breastcancer patients to improve their follow-up and anticipate risky situations or complications, enhancing thus their quality of life! 💡 "This data analysis aims to assess whether there are significant differences in the quality of life between patients classified in the severe osteopenia group and those in the mild osteopenia group. This comparison is crucial for identifying specific needs and adjusting management and treatment strategies". 📈The #REBECCA project leverages #real-world data to provide personalised advice across essential lifestyle areas affecting survivors. This thorough advisory guide ensures a standardised approach across clinical sites, aligning international and local guidelines to enhance patient care. Read the full article ➡️https://lnkd.in/e6bAvVwP Aristotle University of Thessaloniki (AUTH) Karolinska Institutet Stavanger University Hospital Centre for Research & Technology Hellas (CERTH) Harokopio University of Athens Netcompany-Intrasoft Eight Bells Ltd Timelex

Qiming Venture Partners' portfolio company Huimei Technology recently hosted the AI Healthcare Achievements 2024 Review Salon in Shanghai. The event highlighted the impressive impact of Huimei Technology's Clinical Decision Support System (CDSS), which is now deployed in over 1,000 hospitals. During the event, Yu Hongbo, Head of Innovation Business at Huimei Technology, discussed how the CDSS is advancing clinical research, medical management, and cost control. Notably, the system has played a key role in improving quality control, cancer diagnosis and treatment, streamlining follow-up processes, and supporting rare disease screening and diagnosis within hospitals. #AIinHealthcare #CDSS #MedicalInnovation #HealthcareManagement #SmartHealthcare #QimingPortfolio #QimingHealthcare

🎥 Gain insight into customizing BTK inhibitors in clinical practice for 1L #CLL. Watch the full presentation from our recent virtual symposium, led by Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, here 👉 https://loom.ly/gFSly8I #lymsm #lymphoma

VPC is thrilled to share the launch of the M. H. Mohseni Institute of Urologic Sciences! This significant leap forward will foster innovation and enhance translational research for many urologic conditions to positively impact patients in B.C. https://lnkd.in/gJMmGRuQ